Table 2: Main outcomes
| Case n./age/sex |
Uveitis type |
Uveitis duration (yrs) |
Follow-up (mo) |
Attacks 1 (no.) |
Attacks 2 (no.) |
CS 1 (mg/day) |
CS 2 (mg/day) |
Uveitis remission |
| 1/30/M |
OU: PU |
15 |
60 |
6 |
3 |
25 |
25 |
Yes |
| 2/39/M |
OU: PU |
6 |
72 |
1 |
1 |
50 |
0 |
Yes |
| 3/28/M |
OU: Post |
2 |
24 |
1 |
1 |
25 |
0 |
Yes |
| 4/46/F |
OU: Post |
3 |
36 |
2 |
1 |
50 |
5 |
Yes |
| 5/23/M |
OU: Post |
1 |
12 |
1 |
0 |
5 |
5 |
Yes |
| 6/30/M |
RE: PU LE: Post |
4 |
24 |
2 |
0 |
10 |
10 |
No |
| 7/31/M |
OU: Post |
10 |
36 |
1 |
0 |
50 |
0 |
Yes |
| 8/28/F |
LE: PU |
3 |
12 |
2 |
0 |
50 |
0 |
Yes |
| 9/48/F |
OU: PU |
10 |
72 |
9 |
0 |
50 |
0 |
Yes |
| 10/64/F |
LE: PU |
4 |
36 |
3 |
1 |
25 |
0 |
Yes |
| 11/49/F |
OU: AU |
9 |
12 |
2 |
1 |
50 |
5 |
Yes |
| 12/49/M |
OU: PU |
9 |
36 |
2 |
0 |
50 |
10 |
Yes |
| 13/43/M |
OU: PU |
13 |
36 |
4 |
0 |
25 |
25 |
No |
| 14/61/F |
OU: PU |
8 |
12 |
1 |
0 |
25 |
15 |
Yes |
| 15/42/M |
LE: Post |
7 |
15 |
2 |
0 |
25 |
5 |
Yes |
| 16/48/F |
LE: PU |
6 |
6 |
1 |
1 |
50 |
50 |
No |
| 17/32/M |
OU: Post |
1 |
58 |
4 |
1 |
50 |
25 |
No |
| 18/71/F |
OU: AU |
15 |
19 |
1 |
0 |
30 |
25 |
Yes |
| 19/65/F |
RE: AU LE: PU |
9 |
10 |
2 |
0 |
25 |
5 |
Yes |
| 20/20/M |
OU: Post |
1 |
12 |
3 |
0 |
50 |
15 |
Yes |
| 21/26/M |
OU: Post |
10 |
39 |
3 |
0 |
20 |
5 |
Yes |
| 22/47/F |
OU: PU |
12 |
12 |
3 |
0 |
10 |
5 |
Yes |
| 23/32/M |
LE: Post |
4 |
48 |
1 |
1 |
50 |
0 |
Yes |
| 24/28/M |
LE: PU |
3 |
15 |
4 |
0 |
15 |
10 |
Yes |
| 25/62/F |
OU: PU |
13 |
48 |
6 |
1 |
25 |
5 |
Yes |
| 26/34/M |
RE: Post |
5 |
48 |
1 |
0 |
5 |
0 |
Yes |
| 27/37/M |
RE: PU LE:AU |
28 |
72 |
2 |
0 |
10 |
5 |
Yes |
| 28/56/M |
OU: Post |
2 |
18 |
1 |
2 |
25 |
5 |
Yes |
| 29/57/M |
OU: Post |
11 |
36 |
2 |
5 |
10 |
10 |
No |
| 30/32/M |
OU: Post |
1 |
60 |
1 |
0 |
50 |
0 |
Yes |
| 31/13/M |
LE: PU |
1 |
6 |
3 |
0 |
10 |
5 |
No |
| 32/34/M |
OU: PU |
11 |
62 |
5 |
2 |
50 |
0 |
Yes |
Attacks 1: Attacks of uveitis during pre-infliximab period, attacks 2: Attacks of uveitis during infliximab therapy, CS1: Corticosteroids dose at baseline, CS2: corticosteroids dose at last record before beginning of the study, OU: both eyes, RE: Right Eye, LE: Left Eye, PU: Panuveitis, POST: Posterior Uveitis, AU: Anterior Uveitis.